# Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

> **NCT00323882** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 75 (actual)

## Conditions studied

- Prostate Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** MDX-010

## Key facts

- **NCT ID:** NCT00323882
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-09
- **Final completion:** 2013-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2014-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323882, "Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00323882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*